SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Celgene International Sárl Release: Study to Evaluate Dose and Schedule for Oral Epigenetic Therapy CC-486 in Lower-Risk MDS Presented at American Society of Hematology